X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (306) 306
Publication (51) 51
Book Review (33) 33
Conference Proceeding (29) 29
Book Chapter (7) 7
Patent (7) 7
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (177) 177
humans (171) 171
oncology (109) 109
multiple myeloma (91) 91
multiple myeloma - drug therapy (87) 87
hematology (86) 86
multiple myeloma - pathology (56) 56
abridged index medicus (54) 54
male (49) 49
female (48) 48
bortezomib (47) 47
animals (45) 45
mice (41) 41
cell line, tumor (39) 39
multiple myeloma - metabolism (39) 39
aged (34) 34
apoptosis - drug effects (31) 31
middle aged (31) 31
apoptosis (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
bone-marrow (26) 26
dexamethasone (26) 26
therapy (26) 26
adult (24) 24
antineoplastic agents - pharmacology (24) 24
tumor cells, cultured (24) 24
cancer (23) 23
mice, scid (23) 23
article (22) 22
multiple myeloma - genetics (22) 22
survival (21) 21
zoledronic acid (21) 21
in-vivo (20) 20
multiple myeloma - complications (20) 20
multiple myeloma - immunology (20) 20
treatment outcome (20) 20
thalidomide - analogs & derivatives (19) 19
antineoplastic agents - therapeutic use (18) 18
bisphosphonates (18) 18
lenalidomide (18) 18
multiple myeloma - therapy (18) 18
myeloma (18) 18
care and treatment (17) 17
stem-cell transplantation (17) 17
cell proliferation - drug effects (16) 16
chemotherapy (16) 16
health aspects (16) 16
nf-kappa-b (16) 16
xenograft model antitumor assays (16) 16
dexamethasone - administration & dosage (15) 15
multiple-myeloma (15) 15
activation (14) 14
aged, 80 and over (14) 14
boronic acids - pharmacology (14) 14
drug synergism (14) 14
expression (14) 14
multiple myeloma - diagnosis (14) 14
phosphorylation (14) 14
pyrazines - pharmacology (14) 14
cells (13) 13
drug-resistance (13) 13
lymphoid neoplasia (13) 13
patients (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
antitumor-activity (12) 12
carfilzomib (12) 12
disease-free survival (12) 12
growth (12) 12
interleukin-6 (12) 12
lenalidomide plus dexamethasone (12) 12
medicine, general & internal (12) 12
research (12) 12
signal transduction - drug effects (12) 12
combination (11) 11
down-regulation (11) 11
interleukin-6 - pharmacology (11) 11
thalidomide (11) 11
thalidomide - administration & dosage (11) 11
osteoclasts - metabolism (10) 10
analysis (9) 9
bone density conservation agents - adverse effects (9) 9
bone marrow (9) 9
cell biology (9) 9
development and progression (9) 9
diphosphonates - adverse effects (9) 9
diphosphonates - therapeutic use (9) 9
in-vitro (9) 9
marrow stromal cells (9) 9
molecular-mechanisms (9) 9
multiple myeloma - mortality (9) 9
multiple-myeloma cells (9) 9
newly-diagnosed myeloma (9) 9
osteoclasts - drug effects (9) 9
recurrence (9) 9
bone density conservation agents - administration & dosage (8) 8
bone diseases (8) 8
bone marrow - pathology (8) 8
bone marrow cells - pathology (8) 8
boronic acids - administration & dosage (8) 8
caspases - metabolism (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 12/2008, Volume 14, Issue 24, p. 8321
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2008, Volume 14, Issue 24, pp. 8321 - 8321
Journal Article
Blood, ISSN 0006-4971, 06/2010, Volume 115, Issue 25, pp. 5202 - 5213
Aurora-A is a mitotic kinase that regulates mitotic spindle formation and segregation. In multiple myeloma (MM), high Aurora-A gene expression has been... 
OVEREXPRESSION | ACTIVATION | PROTEIN-KINASE | BONE-MARROW | TARGETS | AGENTS | G2 CHECKPOINT | HEMATOLOGY | CANCER | EVENT
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2019, Volume 380, Issue 18, pp. 1726 - 1737
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2019, Volume 380, Issue 22, pp. 2104 - 2115
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2019, Volume 381, Issue 3, pp. e6 - 1737
To the Editor: Raje et al. (May 2 issue) 1 describe the safety profile and antitumor activity of the anti–B-cell maturation antigen (BCMA) chimeric antigen... 
MEDICINE, GENERAL & INTERNAL | Antigens | Antitumor activity | Lymphocytes T | Lymphocytes B | Patients | Multiple myeloma | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e18302 - e18302
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2015, Volume 373, Issue 18, p. 1264
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2019, Volume 25, Issue 16, pp. 4907 - 4916
PURPOSEThe oral proteasome inhibitor oprozomib has shown preclinical antitumor activity. Here, we report phase Ib/II study results investigating single-agent... 
Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 05/2018, Volume 124, Issue 10, pp. 2075 - 2085
Journal Article
American Journal of Hematology, ISSN 0361-8609, 07/2019, Volume 94, Issue 7, pp. 794 - 802
Twice‐weekly carfilzomib (27 mg/m 2 ) with lenalidomide‐dexamethasone (KRd) is a standard‐of‐care in relapsed or refractory multiple myeloma (RRMM). This phase... 
Carfilzomib | Relapse | Dexamethasone | Multiple myeloma | Diseases | Toxicity | Response rates
Journal Article
BLOOD, ISSN 0006-4971, 07/2019, Volume 134, Issue 2, pp. 123 - 133
This phase 1b dose-escalation study evaluated isatuximab plus pomalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Patients... 
SURVIVAL | MANAGEMENT | THERAPY | EFFICACY | DARATUMUMAB MONOTHERAPY | OPEN-LABEL | QUALITY-OF-LIFE | BORTEZOMIB | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | POMALIDOMIDE | Clinical Trials and Observations | 102
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 04/2010, Volume 9, Issue 4, pp. 963 - 975
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2019, Volume 37, Issue 14, pp. 1228 - 1228
PURPOSE To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. METHODS ASCO and Cancer Care... 
ONCOLOGY | PROGRESSION-FREE SURVIVAL | LONG-TERM SURVIVAL | NEWLY-DIAGNOSED MYELOMA | INTERNATIONAL STAGING SYSTEM | QUALITY-OF-LIFE | STEM-CELL TRANSPLANTATION | LOW-DOSE DEXAMETHASONE | MINIMAL RESIDUAL DISEASE | PANOBINOSTAT PLUS BORTEZOMIB | BORTEZOMIB-MELPHALAN-PREDNISONE
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 05/2019
The oral proteasome inhibitor oprozomib has shown preclinical antitumor activity. Here, we report phase 1b/2 study results investigating single-agent oprozomib... 
Journal Article
Skeletal Radiology, ISSN 0364-2348, 5/2019, Volume 48, Issue 5, pp. 773 - 779
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 726 - 736
Journal Article